Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies
- PMID: 26462242
- PMCID: PMC4589089
- DOI: 10.4137/BCBCR.S29420
Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies
Abstract
Breast cancer is the most prevalent cancer among women worldwide. However, increased survival is due to the dramatic advances in the screening methods, early diagnosis, and breakthroughs in treatments. Over the course of the last decade, many acquisitions have taken place in this critical field of research in the pharmaceutical industry. Advances in molecular biology and pharmacology aided in better understanding of breast cancer, enabling the design of smarter therapeutics able to target cancer and respond to its microenvironment efficiently. Patents and research papers investigating diagnosis and treatment strategies for breast cancer using novel technologies have been surveyed for the past 15 years. Various nanocarriers have been introduced to improve the therapeutic efficacy of anticancer drugs, including liposomes, polymeric micelles, quantum dots, nanoparticles, and dendrimers. This review provides an overview of breast cancer, conventional therapy, novel technologies in the management of breast cancer, and rational approaches for targeting breast cancer.
Highlights: Breast cancer is the most common cancer in women worldwide. However, survival rates vary widely, optimistically heading toward a positive trend. Increased survival is due to the drastic shift in the screening methods, early diagnosis, and breakthroughs in treatments.Different strategies of breast cancer classification and staging have evolved over the years. Intrinsic (molecular) subtyping is essential in clinical trials and well understanding of the disease.Many novel technologies are being developed to detect distant metastases and recurrent disease as well as to assess response to breast cancer management.Intensive research efforts are actively ongoing to take novel breast cancer therapeutics to potential clinical application.Most of the recent research papers and patents discuss one of the following strategies: the development of new drug entities that specifically target the breast tumor cells; tailor designing a novel carrier system that can multitask and multifunction as a drug carrier, targeting vehicle and even as a diagnostic tool, direct conjugation of a therapeutic drug moiety with a targeting moiety, diagnostic moiety or pharmacokinetics altering moiety; or the use of innovative nontraditional approaches such as genetic engineering, stem cells, or vaccinations.
Keywords: bioconjugates; breast cancer; conventional modalities; delivery systems; diagnosis; nanocarriers; nanoparticles; novel technology; patents; recent studies; stimuli responsive particles; treatment.
Figures
Similar articles
-
Novel treatment strategies for brain tumors and metastases.Pharm Pat Anal. 2014 May;3(3):279-96. doi: 10.4155/ppa.14.19. Pharm Pat Anal. 2014. PMID: 24998288 Free PMC article. Review.
-
Nanotechnology: an evidence-based analysis.Ont Health Technol Assess Ser. 2006;6(19):1-43. Epub 2006 Nov 1. Ont Health Technol Assess Ser. 2006. PMID: 23074489 Free PMC article.
-
Advances in novel drug delivery strategies for breast cancer therapy.Artif Cells Blood Substit Immobil Biotechnol. 2010 Oct;38(5):230-49. doi: 10.3109/10731199.2010.494578. Artif Cells Blood Substit Immobil Biotechnol. 2010. PMID: 20677900 Review.
-
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Eur J Pharm Biopharm. 2015. PMID: 25813885 Review.
-
A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis.Recent Pat Drug Deliv Formul. 2020;14(2):126-144. doi: 10.2174/1872211314666200914155051. Recent Pat Drug Deliv Formul. 2020. PMID: 32928094 Review.
Cited by
-
Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance.Cancer Drug Resist. 2020 Nov 3;3(4):930-946. doi: 10.20517/cdr.2020.68. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582218 Free PMC article. Review.
-
Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential.Cancers (Basel). 2023 Oct 7;15(19):4879. doi: 10.3390/cancers15194879. Cancers (Basel). 2023. PMID: 37835573 Free PMC article. Review.
-
LINC00963-FOSB-mediated transcription activation of UBE3C enhances radioresistance of breast cancer cells by inducing ubiquitination-dependent protein degradation of TP73.J Transl Med. 2023 May 12;21(1):321. doi: 10.1186/s12967-023-04153-z. J Transl Med. 2023. PMID: 37173692 Free PMC article.
-
Application of Clinical Decision Support System to Assist Breast Cancer Patients with Lifestyle Modifications during the COVID-19 Pandemic: A Randomised Controlled Trial.Nutrients. 2021 Jun 20;13(6):2115. doi: 10.3390/nu13062115. Nutrients. 2021. PMID: 34203025 Free PMC article. Clinical Trial.
-
Attenuative Effect of Diallyl Trisulfide on Caspase Activity in TNF-α-induced Triple Negative Breast Cancer Cells.Anticancer Res. 2023 Jun;43(6):2393-2405. doi: 10.21873/anticanres.16407. Anticancer Res. 2023. PMID: 37247921 Free PMC article.
References
-
- Ebeid NI. Egyptian Medicine in the Days of the Pharaohs. General Egyptian Book Organization; Cairo, Egypt: 1999.
-
- Akram M, Siddiqui SA. Breast cancer management: past, present and evolving. Indian J Cancer. 2012;49(3):277–282. - PubMed
-
- Sanchez GM, Meltzer ES. The Edwin Smith Papyrus: Updated Translation of the Trauma Treatise and Modern Medical Commentaries. Lockwood Press; Atlanta, GA: 2012.
-
- Brayn CP, Smith GE. The Papyrus Ebers, Translated from the German Version. Letchworth, Herts: The Guardian City Press LTD; 1930.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous